> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Arbutus Cash Rises To $337.5 Million From $91.5 Million Before Its Shareholder Payout
- URL: https://www.bullished.co/arbutus-cash-rises-to-337-5-million-from-91-5-million-before-its-shareholder-payout-6546634d/
- Published: 2026-11-10T12:36:17.000Z
- Updated: 2026-11-10T12:36:17.000Z
- Description: A Genevant dividend helped produce a quarterly profit, while Arbutus paid $230 million to repurchase shares in early October.
- Author: Matteo Parrino
- Tags: SEC Filings, ABUS, Industry: Healthcare

[Arbutus Biopharma](https://www.bullished.co/tag/abus/), which is testing treatments for chronic hepatitis B, reported [cash and investments](https://www.sec.gov/Archives/edgar/data/0001447028/000117184326007311/f8k%5F111026.htm?ref=bullished.co) of $337.5 million at September 30, up from $91.5 million at year-end 2025, in Tuesday's SEC filing. The settlement-funded balance preceded a $230 million payment to shareholders in early October.

## Settlement Cash, Then A Buyback

Arbutus completed the payout by [repurchasing 46 million](https://www.sec.gov/Archives/edgar/data/0001447028/000117184326007311/exh%5F991.htm?ref=bullished.co) shares at $5.00 each for cancellation. Those shares represented approximately 23% of the shares outstanding as of September 29; the September 30 balance sheet already included a $230 million obligation for the repurchase.

The money came from patent litigation. Moderna paid $950 million to Arbutus and its exclusive licensee, Genevant Sciences, in July under their March settlement. Arbutus received $178.4 million, including reimbursement for litigation costs, and Genevant distributed a further $67.3 million cash dividend in September from settlement-related earnings.

Arbutus owns about 16% of Genevant's common equity and licenses its patented lipid nanoparticle technology through that business. The particles carry vaccine material, and their use in COVID-19 vaccines is the subject of Arbutus' patent cases.

For the first nine months, operating activities generated $225.7 million in net cash, compared with $35.0 million used a year earlier. Stock-option exercises supplied another $19.3 million.

## Dividend Profit, Higher Operating Loss

The Genevant dividend helped Arbutus earn [$59.1 million](https://www.sec.gov/Archives/edgar/data/0001447028/000117184326007311/exh%5F991.htm?ref=bullished.co), or $0.30 per share, in the third quarter, versus a $7.7 million loss, or $0.04 per share, a year earlier. Its operating loss widened to $10.5 million from $8.7 million.

Quarterly revenue fell to $0.3 million from $0.5 million. Arbutus attributed the decline primarily to lower royalties as Alnylam's ONPATTRO sales decreased.

Administrative expenses reached $8.0 million, against $3.0 million a year earlier. The company attributed most of the increase to one-time cash bonuses for executives' work on the Moderna settlement.

Research spending fell to $2.6 million from $5.8 million. Arbutus credited workforce cuts, its decision to stop in-house scientific research and lower clinical-study costs as trials approached completion. Restructuring expenses were zero, compared with $0.1 million a year earlier.

## More Patent Claims, AB-101 Reopens

Arbutus and Genevant filed additional cases against Pfizer Japan in Tokyo District Court, seeking damages and permanent injunctions. They also added a newly issued lipid nanoparticle patent to their Canadian case against Pfizer, BioNTech and affiliates. In July, they had filed three international lawsuits covering 21 countries.

Arbutus said evidence submitted in a Japanese case included tests of commercial Pfizer/BioNTech samples obtained in the United States and Europe. It contends those samples fall within its lipid-composition patent claims; the infringement claims remain allegations.

The drug portfolio includes injected RNA-interference treatment imdusiran and oral candidate AB-101\. Arbutus announced on October 22 that the FDA had [lifted its hold](https://www.sec.gov/Archives/edgar/data/0001447028/000117184326006753/exh%5F991.htm?ref=bullished.co) on AB-101, permitting additional U.S. clinical development. The company is evaluating how to proceed.

Another potential payment depends on the Federal Circuit. Oral argument took place November 5 on whether federal law bars patent claims involving government-funded Moderna vaccine doses. Under the settlement, Moderna owes an additional $1.3 billion if the appellate ruling permits the claims, apart from doses the district court characterized as going to U.S. government employees.

The appeals decision is forthcoming. That contingent payment remains separate from the $950 million Moderna already paid.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Arbutus Biopharma Corp (ABUS)](https://www.sec.gov/Archives/edgar/data/0001447028/000117184326007311/f8k%5F111026.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exh\_991.htm — Arbutus Biopharma Corp 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001447028/000117184326007311/exh%5F991.htm?ref=bullished.co) — SEC EDGAR
- [8-K filed 2026-10-22 — Arbutus Biopharma Corp (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001447028/000117184326006753/exh%5F991.htm?ref=bullished.co) — SEC EDGAR

### More on Arbutus Biopharma

- [FDA Lifts Clinical Hold On Arbutus's Oral Hepatitis B Drug AB-101; Company Weighs Next Steps](https://www.bullished.co/fda-lifts-clinical-hold-on-arbutuss-oral-hepatitis-b-drug-ab-101-company-weighs-next-steps-20710121/)
- [Roivant Tendered 8,967,383 Arbutus Shares At $5.00 To Keep Its 19.5% Stake Intact](https://www.bullished.co/roivant-tendered-8-967-383-arbutus-shares-at-5-00-to-keep-its-19-5-stake-intact-72feb419/)

[All Arbutus Biopharma (ABUS) coverage →](https://www.bullished.co/tag/abus/)